Molecular Genomics in Brain Tumors
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 44
Special Issue Editors
2. Center for Translational Research on Autoimmune and Allergic Disease (CADD), Corso Trieste 15A, 28100 Novara, Italy
Interests: brain tumors; cancer research; molecular genetics; genomics; metagenomics; transcriptomics
Special Issues, Collections and Topics in MDPI journals
2. Pathology Unit, Maggiore della Carità Hospital, 28100 Novara, Italy
Interests: pathology; molecular pathology; cytopathology; biomarkers of clinical interest in malignant pleural mesothelioma; colorectal carcinoma; lung cancer; malignant melanoma; thyroid tumors; viral carcinogenesis (polyomavirus and papillomavirus)
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gliomas are frequent and malignant primary brain tumors in adults and pediatric patients. Besides several translational and clinical studies in the last few years, gliomas remain the most lethal neoplasm in the central nervous system.
This Special Issue aims to collect findings and innovations in this research field, including the molecular landscape of gliomas, the tumor microenvironment, the microbiota–gut–brain-axis, cell cross-talk, transcriptomics, epigenomics, proteomics and metabolomics studies, or therapeutics advances.
Potential topics include, but are not limited to, the following:
- Technical advancement in gold-standard neuro-imaging procedures;
- Advances in the molecular genetics of gliomas using next-generation techniques with implications for classification and therapy;
- The tumor microenvironment in the discovery of new therapeutic biomarkers;
- The microbiota–gut–brain axis;
- Introductions, in clinics, of novel therapeutic options.
We are pleased to invite you to participate in this Special Issue by presenting original research articles, clinical studies, multi-omics analysis, or reviews, as well as new ideas and hypotheses on all aspects related to molecular mechanisms, diagnostic and prognostic biomarkers, pre-clinical models, and therapeutic options for gliomas.
Marta Mellai and Renzo Boldorini
Dr. Marta Mellai
Prof. Dr. Renzo Boldorini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- signaling pathways
- metabolism
- microbiota–gut–brain axis
- biomarkers
- therapeutics
- immunotherapy
